Federal contract award
75N93019C00059
TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018
Award details
Obligations, current value and potential value describe different measures; they are never added together.
| Field | Reported value |
|---|---|
| Agency | Department of Health and Human Services |
| Office | NATIONAL INSTITUTES OF HEALTH NIAID |
| NAICS | 541714 — Research and Development in Biotechnology (except Nanobiotechnology) |
| PSC | AN12 — HEALTH R&D SERVICES; HEALTH CARE SERVICES; APPLIED RESEARCH |
| Parent award / vehicle | Not reported |
| Set-aside | NO SET ASIDE USED. |
| Pricing type | COST PLUS FIXED FEE |
| Obligations | $13.8M |
| Current contract value | $13.8M |
| Potential contract value / ceiling | $16.7M |
| Start date | Sep 9, 2019 |
| Current end date | Apr 25, 2025 |
| Potential end date | Apr 25, 2025 |
| Latest award activity | Aug 31, 2026 |
| Source loaded | Sep 26, 2026 |
Funding and modification history
Showing the latest 20 of 20 loaded transactions. Negative values are deobligations.
| Date | Modification | Obligation change | Description |
|---|---|---|---|
| Aug 31, 2026 | P00019 | $-11.6K | TO ADMINISTRATE DE-OBLIGATE UNEXPENDED AND EXPIRING FISCAL YEAR 2021 FUNDING IN ACCORDANCE WITH 31 U.S.C. SECTION 1552 (A), IN PREPARATION FOR SEPTEMBER 30, 2026, CLOSING OF THE PERIOD OF AVAILABILITY OF THESE FISCAL YEAR FUNDS. |
| Apr 25, 2025 | P00018 | $0 | EOI::IMPLEMENTING THE PRESIDENTS DEPARTMENT OF GOVERNMENT EFFICIENCY COST EFFICIENCY INITIATIVE (MARCH 19, 2025)::EOI TERMINATE FOR CONVENIENCE - FULL. |
| Dec 4, 2024 | P00017 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Sep 10, 2024 | P00016 | $113.1K | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Jul 22, 2024 | P00015 | $1.9M | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Jul 2, 2024 | P00014 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Apr 16, 2024 | P00013 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Jan 9, 2024 | P00012 | $779.9K | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Dec 22, 2023 | P00011 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Sep 29, 2023 | P00010 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Aug 28, 2023 | P00009 | $1.7M | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Apr 12, 2023 | P00008 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Dec 8, 2022 | P00007 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Aug 1, 2022 | P00006 | $3.5M | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Jun 9, 2021 | P00005 | $2.7M | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Apr 26, 2021 | P00004 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Mar 25, 2020 | P00003 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Jan 22, 2020 | P00002 | $0 | THE CONTRACTOR SHALL DEVELOP A MULTIVALENT FLAVIVIRUS VACCINE USING A FLEXIBLE REPLICATION RNA PLATFORM. |
| Sep 9, 2019 | P00001 | $0 | TO CHANGE THE PI, ADD AN ALTERNATE COR, AND INCORPORATE FAR CLAUSES 52.204-25 AND 52.244-6. |
| Aug 29, 2019 | 0 | $3.1M | TO MAKE AN AWARD UNDER HHS-NIH-NIAID-BAA2018 |
Research next steps
- Check the stated set-aside against the solicitation and current certifications.
- Review the award scope and buyer evidence before making a bid/no-bid decision.